Surge in Cannabis Smuggling Prompts Thailand to Tighten Rules
Dispensaries will be allowed to sell cannabis only to those with licenses or with prescriptions from medical professionals, including traditional medicine practitioners, when proposed changes to existing rules take effect in about 40 days. The amount sold will also be limited to 30 days of use, according to the Ministry of Public Health.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
a day ago
- Bloomberg
Using AI to Track and Treat Allergies
Hi, it's Karoline in Singapore, where hay fever is very common. Now a new AI-driven program led by a public hospital here is trying to build a database to better understand the condition. But before I tell you how and why ... I have hay fever, also known as allergic rhinitis, and am not always sure whether or not I should see a doctor, because my symptoms can be hard to predict. One morning, they could be too minor to bother a doctor, but turn very bad the next, with my breathing strained. I wish there was a doctor near me available 24 hours a day to prescribe medication or give me a treatment plan.
Yahoo
a day ago
- Yahoo
Officials push for ban that could wipe popular product from shelves: 'In line with public health aspirations'
Officials push for ban that could wipe popular product from shelves: 'In line with public health aspirations' With many countries concerned about the effects of the vape industry on their citizens, Malaysia has taken a definitive stance on the hot topic. Historically known to cause long-lasting health issues, vapes affect not only those who use them but also those who breathe in secondhand smoke. The risks to lung stability, the possibility of nicotine addiction, and, if used for long periods, the cause of some cancers make vaping a continuous worldwide problem. However, the Straits Times reported that the health minister of Malaysia, Dzulkefly Ahmad, has taken a firm position on removing the harmful products from the country altogether. He aims to further push the regulation of vape products, as detailed in the Control of Smoking Products for Public Health Act 2024, titled Act 852. Thus far, six Malaysian states have decided to stop renewing their vape licenses and stop issuing them altogether. Already, the push for regulation on vape products has taken significant strides toward increased community health. Dr. Dzulkefly stated, "This is in line with public health aspirations and the premise licensing powers under local governments." Where there were originally "3,200 brands" with "6,800 variants" in Malaysia, after the implementation of Act 852, there are now "only 390 brands" with "2,794 variants," per the Straits Times. The sharp decrease in options bodes well for public health. With less access to vapes and vape products, people are far less likely to fall into addiction. Other countries, such as Kazakhstan and Australia, are taking similar steps to ban the products. In response to the news, users took to Reddit to voice their concerns, with one user saying, "You can't upright ban something just like that. … Straight ban [equals] the other party will just find a way to find a loophole." Another said that "people are going to consume nicotine anyway" and that "the goal is harm reduction." Do you think nonstick cookware should be illegal nationwide? Yes No way Let each state decide I'm not sure Click your choice to see results and speak your mind. "We need more long-term, longitudinal studies on the effects of vapes on human health," they added. Dr. Dzulkefly said the government will facilitate solutions for those concerned about going "cold turkey," having developed an addiction to the vapes they regularly purchase. "The 111 one-stop centres for addiction (OSCA) and 857 smoking cessation clinics are ready to serve," Dzulkefly said, according to the Straits Times. This way, those who will need to wean themselves off of vaping will have access to some care and assistance to quit and work toward a healthier lifestyle. Additionally, with vapes being limited for consumers, e-waste is greatly reduced. Many vapes that are heralded as disposable contain non-biodegradable materials that pose a fire or contamination risk when carelessly thrown out as litter or while sitting in a landfill. With the crackdown on vape sales and usage in Malaysia, waste that cannot be broken down and seeps into the environment will be greatly reduced. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
Forbes
2 days ago
- Forbes
Truckin' To 2030: Europe's Green Horizon For Medical Cannabis & Hemp
Europe's cannabis sector is undergoing a profound transformation—one driven by evolving regulations, changing social attitudes, and rising institutional investor interest. Germany, as the continent's largest economy, stands at the heart of this transition, leading a dual trajectory in both medical cannabis and industrial hemp. What was once niche is now positioned as a cornerstone of sustainable health, clean materials, and innovative investment opportunities. You might say that the European industry appears to be built to last. Market Overview and Segmentation Europe's cannabis landscape is divided into two distinct segments: THC‑containing cannabis (above 0.3% THC), regulated primarily for medical and sometimes adult-use purposes; and industrial hemp (below 0.3% THC), employed in foods, textiles, bioplastics, cosmetics, and construction. While sharing a botanical origin—Cannabis sativa L.—each operates under its own regulatory framework, supply chain, and market focus. Understanding this segmentation is essential for investors and policymakers evaluating risk and opportunity. Globally, the medical cannabis market was valued at approximately €4.5 billion in 2024 and is projected to reach over €62 billion by 2030—recording a staggering compound annual growth rate (CAGR) of 55%. Europe, fueled by demographic shifts and legal liberalization, is forecasted to be the fastest-growing region. Meanwhile, the industrial hemp market is poised to triple to around €15 billion by 2030, according to UNCTAD projections, driven by surging demand for climate-friendly materials and plant-based nutrition. Regulatory Developments The eyes of the world are on Germany, as it has emerged as the regulatory focal point in Europe. Its Cannabis Act (CanG), enacted in 2024, removed restrictive quotas and significantly expanded medical access. A complementary Medical Cannabis Act (MedCanG) is under development, emphasizing pharmacy-based distribution while tightening telemedicine channels. In parallel, a new Industrial Hemp Liberalization Act is expected in 2026, poised to eliminate outdated restrictions and modernize hemp production regulation. On the EU level, the classification of CBD as a Novel Food is opening doors to wellness and nutrition markets previously inaccessible for hemp producers. Growth in Medical Cannabis Since medical cannabis legalization in 2017, German patient numbers have soared—with 300,000 individuals receiving prescriptions in 2024, estimated to grow to 840,000 in 2025. By 2030, the market is expected to reach €650 million. Innovations in formulation—such as high-purity extracts, dronabinol pills, and cannabinoid pastilles—are expanding therapeutic use across neurology, chronic pain, and oncology. Major operators like SYNBIOTIC SE are leading the charge, developing standardized dosage forms and investing in regulated production. Global companies such as Tilray, Aurora, OrganiGram, and Canada's Sanity Group (via its partnership with OrganiGram) are deepening their European presence, underlining the continent's rising magnetism for international cannabis investors. Industrial Hemp as a Sustainability Engine Industrial hemp, long undervalued, is now recognized as a strategic asset in Europe's green economy. German industrial hemp sales grew from €526 million in 2023 to a projected €3 billion by 2032 (CAGR ~22%). Applications range from hemp-protein powders to sustainable building insulation and biodegradable packaging. EU regulatory shifts—especially Novel Food approvals for CBD—further enable consumer-facing products. Companies such as Hempro International and new-era ventures targeting hemp-based construction materials and plant-based supplements illustrate the growing breadth of the market. Investment Opportunities and Strategic Challenges Europe is increasingly attractive to North American capital. SYNBIOTIC SE exemplifies a diversified strategy, combining medical cannabis and hemp under a unified corporate model. The publicly traded holding company expects revenues to climb from €26 million in 2025 to €47 million by 2027, with positive EBITDA forecasted in 2026. This dual exposure provides a hedge against regulatory divergence and price compression in either sector. David Hyde, founder and CEO of Hyde Advisory & Investments, plays a pivotal role in monitoring and facilitating cannabis investments in Germany. Through his firm's expert brokerage services, Hyde navigates complex regulatory frameworks, matches strategic partners, and helps investors identify high-quality medical cannabis assets in the German market. Drawing from his firm's insights, Hyde notes: Germany's medical cannabis market continues to grow, albeit more slowly than Australia's. While German market competition is increasing, there is lots of room for new brand/category entrants with proper market research, understanding of developed cannabis markets and the right distribution partner(s)." Several industry leaders are confident that Europe represents the next major frontier for cannabis investment. As Boris Jordan, Executive Chairman of Curaleaf, put it, '[Europe is the next big market for cannabis after the U.S.]' Meanwhile, Irwin Simon, CEO of Tilray, emphasizes the scale of the opportunity: 'Germany's de-scheduling of cannabis opens the path to new opportunities in a potential $3 billion medical market; the European Union medical cannabis market is now projected to become $45 billion.' Constantin von der Groeben, founder of Demecan, reflects on Germany's growth momentum: 'The market is on a constant growth that is overwhelming,' while Beau Whitney, head economist at Whitney Economics, sees a broader European transformation underway: 'We can expect an accelerated expansion in the EU of legalised cannabis… If countries reform quickly, then the EU could supplant the U.S. as the major leader in global cannabis reform.' Yet investors must navigate risks: regulatory uncertainty (especially around telemedicine and CBD policy), intense price competition as production scales, limited banking integration, and macroeconomic volatility. The fragmented legal landscape further complicates capital deployment in cannabis-related ventures. Why Legalization Is Working The legalization model in Europe—and particularly in Germany—has shown measurable success. Its framework promotes transparency, standards for safety and quality, and integration into conventional health systems. The emphasis on licensing, standardized extracts, and court-regulated pharmacies mirrors a methodical approach, providing market certainty for investors and patients alike. Moreover, reform frameworks that prioritize illicit-market conversion—such as transitioning traditional, unregulated growers into legal cooperatives—mirror best practices championed by analysts like Whitney Economics. This conversion aligns economic incentives, reduces social harms, and demonstrates the sustainability of the legal regime. Outlook to 2030 As of 2025, both medical cannabis and industrial hemp are poised to become multibillion-euro pillars of Europe's economy. By 2030, medical cannabis in Europe could exceed €10 billion, while industrial hemp ascends as an eco-driven mainstay. Companies rooted in innovation, regulatory compliance, and product diversification will lead market consolidation. Germany will remain the driving force behind this evolution—acting as the regulatory pioneer and investment hub for cannabis in Europe. Institutional and private investors seeking long-term value should consider pan-European platforms that bridge both cannabis segments, such as publicly traded SYNBIOTIC SE. Their IFRS-audited integrated model reflects the shift to a new chapter in medicine and an innovative sustainable economy. END NOTES: CanG Gesetz 2024 – UNCTAD 2022 – Cannabissciencetech 2024 – CannaMonitor 2025 – Credence Research – Grand View Research – IMARC Group – Luminorecruit 2025 – MJBizDaily 2024 – Novel Food – OrganiGram/Sanity Group 2024 – Research And Markets 2024 – Reuters 2024 – Statista – Weedman 2025 –
